Platelets and atherothrombosis: Causes, targets and treatments for thrombosis

Current Medicinal Chemistry

Volumn 20, Issue 22, 2013, Pages 2779-2797

  Siddiqui, T I ^a   A Kumar, K S ^a   Dikshit, D K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

ADP; Atherothrombosis; Collagen; Fibrinogen; Platelet receptor antagonists; Platelets; Thrombin; Thromboxane

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARC 669931MX; CANGRELOR; CLOPIDOGREL; DAZOXIBEN; ELAROFIBAN; ELINOGREL; EPTIFIBATIDE; FRADAFIBAN; GANTOFIBAN; INDOBUFEN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; ORBOFIBAN; PRASUGREL; RIDOGREL; ROXIFIBAN; RWJ 3308; SB 214587; SIBRAFIBAN; SULFINPYRAZONE; SULOTROBAN; TERUTROBAN; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XEMILOFIBAN;

ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BOLUS INJECTION; BRAIN ISCHEMIA; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG URINE LEVEL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; IC 50; LOW DRUG DOSE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REPEATED DRUG DOSE; SECONDARY PREVENTION; SINGLE DRUG DOSE; STOMACH ULCER; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84880307477     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320220004     Document Type: Article

References (197)

1. Rosamond, W.; Flegal, K.; Friday, G.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lloyd, J. D.; McDermott, M.; Meigs, J.; Moy, C.; Nichol, G.; O'Donnell, C.J.; Roger, V.; Rumsfeld, J.; Sorlie, P.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Hong, Y. Heart Disease and Stroke Statistics-2010 Update : A Report From the American Heart Association. Circulation, 2010: E47-e215.
2. Kohn, D. Getting to the heart of the matter in India. The Lancet, 2008, 372, 523-524
3. Michelson, A D. Platelets 2nd edn. Elsevier/Academic Press, San Diego, 2007.
4. Alan, D. M. Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews: Drug Discovery, 2010, 9, 154-169.
5. Hoak, J.C. Platelet and atherosclerosis. Thromb Hemost, 1988, 14, 202-205.
6. Rabbani, L.E.; Loscalzo, J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis, 1994, 105, 1-7.
7. David, A. V.; Richard, B. Platelets in atherothrombosis. Mayo Clin Proc., 2006, 81(1), 59-68
8. Italiano, J. E.; Hartwig, J. H.; Platelets 2nd edn, Elsevier/Academic Press, San Diego, 2007, 23-44.
9. Roderique, E. M.; Wynands, J. E.; Blood coagulation and haemostasis: A review. Can. Anaes. Soc. J., 1967, 14(2), 129-151.
10. Smith, A. S.; The cell-based model of coagulation. Journal of Veterinary Emergency and Critical Care. 2009, 19(1), 3-10.
11. Stephen, M. P.; Esperanza, P.; Louis, V.; Neil, A. H. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation; Treatment with recombinant factor VIIa. Chest, 2003,124, 2400-2403.
12. Denis, C. V.; Wagner, D. D. Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 728-739.
13. Zaverio, M. R. Platelets in atherothrombosis. Nature Medicine, 2002, 8(11), 1227-1234
14. Farndale, R.W.; Sixma, J.J.; Barnes, M.J.; De Groot, P.G. Role of collagen in thrombosis and haemostasis. J. Thromb. Haemost., 2004, 2, 561-573.
15. Richard, W. F. Collagen-induced platelet activation. Blood Cells, Molecules, and Diseases, 2006, 36, 162-165.
16. Plenz, G.A.; Deng, M.C.; Robenek, H; Volker, W. Vascular collagens: Spotlight on the role of type VIII collagen in atherogenesis. Artherosclerosis, 2003, 166, 1-11.
17. Saelman, E.U.; Horton, L.F.; Barnes, M.J.; Gralnick, H.R.; Hese, K.M. Nieuwenhuis, H.K. Platelet adhesion to cyanogen-bromide fragments of collagen alpha 1(I) under flow conditions. Blood, 1993, 82, 3029-3033.
18. Murata, K.; Motayama, T.; Kotake, C. Collagen types in various layers of the human aorta and their changes with the atherosclerotic process. Atheroclerosis, 1986, 60, 251-262.
19. Nieuwenhuis, H.K.; Akkerman, J.W.; Houdijk, W.P.; Sixma, J.J. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985, 318, 470-472.
20. Santoro, S.A. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell, 1986, 46, 913-920.
21. Santoro, S.A.; Zutter, M.M. The alpha 2 beta 1 inte integrin: A collagen receptor on platelets and other cells. Thromb Haemost. 1995, 74, 813-821
22. Clemetson, K.J.; McGregor, J.L.; James, E.; Dechavanne, M.; Luscher, E.F. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J. Clin. Invest., 1982, 70, 304-311.
23. Jandrot-Perrus, M.; Busfield, S.; Lagrue, A.H. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: A platelet-specific collagen receptor from the immunoglobulin superfamily. Blood, 2000, 96, 1798-1807.
24. Clemetson, J.M.; Polgar, J.; Magnenat, E.; Wells, T.N.; Clemetson, K.J. The Platelet Collagen Receptor Glycoprotein VI Is a Member of the Immunoglobulin Superfamily Closely Related to FcαR and the Natural Killer Receptors J. Biol. Chem., 1999, 274, 29019-29024.
25. Surin, W.R.; Barthwal, M.K.; Dikshit, M. Platelet collagen receptors, signaling and antagonism: Emerging approaches for the prevention of intravascular thrombosis. Thromb Res., 2008, 122, 786-803.
26. Penz, S.; Reininger, A.J.; Brandl, R.; Goyal, P.; Rabie, T.; Bernlochner, I.; Rother, E.; Goetz, C.; Engelmann, B.; Smethurst, P.A.; Ouwehand, W.H.; Farndale, R.; Nieswandt, B.; Siess, W. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J, 2005, 19, 898-909.
27. Cosemans, J.M.; Kuijpers, M.J.; Lecut, C.; Loubele, S.T.; Heeneman, S.; Jandrot-Perrus, M.; Heemskerk, J.W.; Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. Atherosclerosis, 2005, 181, 19-27.
28. Bernhard, N.; Steve, P. W. Platelet-collagen interaction: Is GPVI the central receptor? Blood, 2003, 102(2), 449-461
29. Savage, B.; Ruggeri, Z. M. Platelets. San Diego, CA: Academic Press, 2002: 215-228.
30. Lopez, J. A.; Berndt, M. C. Platelets. San Diego, CA: Academic Press, 2002: 85-97.
31. John, J. D.; Kumar, R.; Seehra, J.; Somers, S. S.; Lidia, M. Crystal Structure of the GpIbα-Thrombin Complex Essential for Platelet Aggregation. Science, 2003, 301, 222-226
32. Ruggeri, Z. M. Mechanisms initiating platelet thrombus formation. Thromb. Haemost., 1997, 78, 611-616.
33. Savage, B.; Saldivar. E.; Ruggeri, Z. M. Initiation of platelet adhesion by attachment onto fibrinogen or translocation on von Willebrand factor. Cell, 1996, 84, 289-297
34. Siess, W. Molecular mechanisms of platelet activation. Physiol Rev., 1989, 69, 158-178.
35. Hourani, S.M.O.; Hall, D.A. Receptors for ADP on human platelets.Trends Pharmacol. Sci., 1994, 15, 103-108.
36. Mills, D.C.B. ADP receptors on platelets. Thromb Haemost., 1996, 76, 835-856.
37. Gachet, C.; Hechler, C.; Leon, C.; Vial, C.; Ohlmann, P.; Cazenava, J. Purinergic receptors on blood platelets. Platelets, 1996, 7, 261-267.
38. Puri, R.N.; Colman, R.W. ADP-induced platelet activation. Crit. Rev. Biochem. Mol. Biol., 1997, 3, 432-507.
39. Gachet, C.; Cazenave, J.P. Platelet receptors: ADP in Platelets in Thrombotic and Non-thrombotic Disorders, Cambridge University Press, Cambridge, 2002: 127-139.
40. Marcin, R.; Marek, N.; Cezary W. Adenosine diphosphate receptors on blood platelets: Potential new targets for antiplatelet therapy. Acta Biochimica Polonica, 2005, 52(2), 411-415.
41. Ralevic, V.; Burnstock, G.; Receptors for Purines and Pyrimidines. Pharmacol. Rev., 1998, 50, 413-492.
42. Gachet, C. ADP receptors of platelets and their inhibition.Thromb Haemost., 2001, 86, 222-232.
43. MacKenzie, A.B.; Mahaut-Smith, M.P.; Sage, S.O. Activation of Receptor-operated Cation Channels via Purinoceptors in Human Platelets. J. Biol. Chem., 1996, 271, 2879-2881.
44. Jin, J.; Quinton, T.M.; Zhang, J.; Rittenhouse, S.E.; Kunapuli, S.P. Adenosine diphosphate (ADP)-induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin alphaIIbbeta3 and ADP receptors. Blood, 2002, 99, 193-198.
45. Coughlin, S. R. How thrombin "talks" to cells: Molecular mechanisms and roles in vivo. Arterioscler. Thromb Vasc. Biol., 1998, 18, 514-518.
46. Hung, D. T.; Wong, Y. H.; Vu, T. K.; Coughlin, S. R. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinoside hydrolysis and inhibit adenylyl cyclase. J. Biol. Chem., 1992, 267, 20831-20834
47. Covic, L.; Gresser, A. L.; Kuliopulos, A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membranetethered peptides. Biochemistry, 2000, 39, 5458-5467.
48. Vassallo, R. R.; Jr Kieber-Emmons, T.; Cichowski, K.; Brass, L. F. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J. Biol. Chem., 1992, 267, 6081-6085.
49. Macfarlane, S.R.; Seatter, M.J.; Kanke, T.; Hunter, G.D.; Plevin, R. Proteinase-Activated Receptors. Pharmacol. Rev., 2001, 53, 245-282.
50. Vu, T. K.; Hung, D. T.; Wheaton, V. I.; Coughlin, S. R.; Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 1991, 64, 1057-1068.
51. Bennett, J.S. Structure and function of the platelet integrin αIIbβ;3. J. Clin. Invest., 2005, 115, 3363-3369.
52. Pitchaiah, M.; Perumal, T.; Thomas, A. K. IIb/IIIa antagonists in acute ischaemic stroke: Current sta-tus and future directions. Drugs, 2008, 68(8), 1019-1028.
53. George, J.N.; Caen, J.P.; Nurden, A.T. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood, 1990, 75, 1383-1395.
54. Shattil, S.J.; Newman, P.J. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood, 2004, 104, 1606-1615.
55. Lefkovits, J.; Plow, E.F.; Topol, E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med., 1995, 23, 1553-1559.
56. Coller, B.S. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest., 1997, 100, S57-S60.
57. Tscheng, J.E. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. J. Cardiol., 1996, 78, 35-40.
58. Coller, B.S. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost., 1997, 78, 730-735.
59. Topol, E.J.; Byzova, T.V.; Plow, E.F. Platelet GPIIb-IIIa blockers. Lancet, 1999, 353, 227-231.
60. FitzGerald, G.A.; Healy, C.D. Thromboxane A2 biosynthesis in human disease. J. Fed Proc., 1987, 46, 154-158.
61. Motoki, M.; Tanaka, A.; Fujisawa, C.; Kawamoto, K.; Itakura, A.; Takaku, M.; Hironaka, T.; Sawada, S.; Matsuda, H. Necessity of Thromboxane A2 for Initiation of Platelet-Mediated Contact Sensitivity: Dual Activation of Platelets and Vascular Endothelial Cells. J. Immunol., 2001, 166, 617-623.
62. Hourani, S. M.; Cusack, N. J. Pharmacological receptors on blood platelets. Pharmacol. Rev., 1991, 43, 243-298
63. Shen, R. F.; Tai, H.H. Thromboxanes: Synthase and receptors J. Biomed. Sci., 1998, 5, 153-172.
64. FitzGerald, G. A. Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. Am. J. Cardiol., 1991, 68, 11B-15B.
65. Benjamin, Z. S.; Paul, J. J.; Satya, P. K. Molecular mechanism of thromboxane A2-induced platelet aggregation essential role for P2TAC and α2A receptors. J. Biol. Chem., 1999, 274(41), 29108-29114.
66. Spalding, A.; Vaitkevicius, H.; Dill, S.; MacKenzie, S.; Schmaier, A.; Lockette, W. Mechanism of Epinephrine-Induced Platelet Aggregation. Hypertension, 1998, 31, 603-607.
67. Simon, F. D. M.; Karen, V.; Katleen, B.; Isabelle, I. S.; Hans, D. Antiplatelet drugs. Br. J. Haematol., 2008, 142, 515-528.
68. Massimo, F.; Giuseppe, L. The role of von Willebrand Factor in hemorrhagic and thrombotic disorders. Crit. Rev. Clin. Lab. Sci., 2007, 44(2), 115-149.
69. Kasirer-Friede, A.; Cozzi, M.R.; Mazzucato, M.; De Marco, L.; Ruggeri, Z.M.; Shattil, S.J. Signal Transduction Blood, 2004, 103, 3403-3411.
70. Ruggeri, Z.M. Old concepts and new developments in the study of platelet aggregation. J. Clin. Invest., 2000, 105, 699-701.
71. Savage, B.; Ruggeri, Z.M. Platelets, Academic Press, 2002, 215-228.
72. De Marco, L.; Girolami, A.; Russell, S, Ruggeri, Z. M. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation J. Clin. Invest., 1985, 75, 1198-1203.
73. Savage, B.; Saldivar, E.; Ruggeri, Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell, 1996, 84, 289-297.
74. Zaverio, M.; Ruggeri, Z.M. Platelets in atherothrombosis Nat. Med., 2002, 8(11), 1227-1234.
75. Kamath, S.; Blann, A. D.; Lip, G. Y. H. Platelet activation: Assessment and quantification European Heart Journal, 2001, 22, 1561-157
76. Todd, L. K.; Richard, C. B. Inhibitors of Platelet Adhesion, Circulation, 2009, 120, 2488-2495.
77. Samara, W.M.; Gurbel, P.A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron. Artery Dis., 2003, 14, 65-79.
78. Ferguson, J.J.; Quinn, M.; Moake, J. L. Antiplatelet Therapy in Clinical Practice, London, 2000, 15-34.
79. Kuwahara, M.; Sugimoto, M.; Tsuji, S. Platelet Shape Changes and Adhesion Under High Shear Flow. Arterioscler. Thromb Vasc. Biol., 2002, 22, 329-334.
80. David, A. V.; Richard, B. Platelets in atherothrombosis. Mayo Clin. Proc., 2006, 81(1), 59-68.
81. Nieswandt, B.; Aktas, B.; Moers, A.; Sachs, U. J. H. Platelets in atherothrombosis: Lessons from mouse models. J. Thromb Haemost., 2005, 3, 1725-1736.
82. Willoughby, S.; Holmes, A.; Loscalzo, J. Platelets and Cardiovascular Disease. Eur. J. Cardiovasc. Nurs., 2002, 1, 273-288.
83. Varga, S.D.; Pleines, I.; Nieswandt, B. Cell Adhesion Mechanisms in Platelets. Arterioscler. Thromb Vasc. Biol., 2008, 28, 403-412.
84. Cattaneo, M. Platelets 2nd ed. Elsevier, Academic Press, San Diego, 2007, 201-220.
85. Conley, P.B.; Delaney, S.M. Scientific and therapeutic insights into the role of the platelet P2Y1 2 receptor in thrombosis Curr. Opin. Hematol., 2003, 10, 333-338.
86. Ding, Z.; Kim, S.; Dorsam, R.T.; Jin, J.; Kunapuli, S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood, 2003, 101, 3908-3914.
87. Thebault, J.J.; Blatrix, C.E.; Blanchard, J.F.; Panak, E.A. Effect of ticlopidine treatment on liver metabolizing enzymes in man. Clin. Pharmacol. Ther., 1975, 18, 485-490.
88. Michelson, A. D. P2Y12 Antagonism, Promises and Challenges. Arterioscler. Thromb Vasc. Biol., 2008, 28, S33-S38.
89. Bertrand, M. E.; Rupprecht, H. J.; Urban, P.; Gershlic, A. H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation, 2000, 102, 624-629
90. Balsano, F.; Rizzon, P.; Violi, F.; Scrutinio, D.; Cimminiello, C.; Aguglia, F.; Pasotti, C.; Rudelli, G. Antiplatelet Treatment with Ticlopidine inUnstable Angina. Circulation, 1990, 82, 17-26.
91. Bhatt, D.L.; Hirsch, A.T.; Ringleb, P.A.; Hacke, W.; Topol, E.J. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am. Heart J., 2000, 140, 67-73.
92. Bhatt, D. L.; Marso, S.P.; Hirsch, A.T.; Ringleb, P. A.; Hacke, W.; Topol, E. J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol., 2002, 90, 625-628.
93. Bhatt, D. L.; Chew, D. P.; Hirsch, A. T.; Ringleb, P. A.; Hacke, W.; Topol, E. J. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001, 103, 363-368.
94. Ringleb, P.A.; Bhatt, D.L.; Hirsch, A.T.; Topol, E. J.; Hacke, W. benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 2004, 35, 528-532.
95. Jakubowski, J. A.; Winters, K. J.; Naganuma, H.; Wallentin, L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev., 2007, 25, 357-374.
96. Wallentin, L.; Varenhorst, C.; James, S. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J., 2008, 29, 21-30.
97. Payne, C. D.; Li, Y. G.; Small, D. S. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J. Cardiovasc. Pharmacol., 2007, 50, 555-562.
98. Farid, N. A.; Smith, R. L.; Gillespie, T. A. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos., 2007, 35, 1096-1104.
99. Sugidachi, A. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J. Thromb Haemost., 2007, 5, 1545-1551.
100. Brandt, J. T. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J., 2007, 153(1), 66, e9-16.
101. Jernberg, T. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur. Heart J., 2006, 27, 1166-1173.
102. Wiviott, S. D.; Braunwald, E.; Angiodillo, D. J. Prasugrel versul clopidogrel in patient with acute coronary syndromes. N. Eng. J. Med., 2007, 357, 2001-2015.
103. Wiviott, S. D. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation, 2007, 116, 2923-2932.
104. Michelson, A. D. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J., 2009, 30, 1753-1763.
105. Nassim, M. A.; Sanderson, J. B.; Clarke, C. Investigation of the novel P2T receptor antagonist AR C69931MX on ex vivo adenosine diphosphate induced platelet aggregation and bleeding time in healthy volunteers. J. Am. Coll. Cardiol., 1999, 33(2), SA, p: 255A.
106. Ingall, A.H.; Dixon, J.; Bailey, A. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy. J. Med. Chem., 1999, 42, 213-220.
107. Huang, J.; Driscoll, E. M.; Gonzales, M. L. Prevention of Arterial Thrombosis by Intravenously Administered Platelet P2T Receptor Antagonist AR-C69931MX in a Canine Model J. Pharmacol. Exp. Ther., 2000, 295, 492-499.
108. van Giezen, J. J.; Humphries, R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonist. Thromb Hemost., 2005, 31, 195-204.
109. Tantry, U. S.; Bliden, K. P.; Gurbel, P. A. AZD6140. Expert Opin. Investig. Drugs, 2007, 16, 225-229.
110. Husted, S. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin Eur. Heart J., 2006, 27, 1038-1047.
111. Cannon, C. P. Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J. Am. Coll. Cardiol., 2007, 50, 1844-1851.
112. Storey, R. F. Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. J. Am. Coll. Cardiol., 2007, 50, 1852-1856.
113. Gretler, D. D.; Conley, P. B.; Andre, P.; Jurek, M.; Pandey, A.; Ronanko, K.; Leese, P. T.; Phillips, DR. J. "First in human" experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for IV and oral use. Am. Coll. Cardiol., 2007, 49(suppl. 2), 326A.
114. Boyer, J. L.; Romero-Avila, T.; Schachter, J. B.; Harden, T. K. Identification of competitive antagonists of the P2Y1 receptor. Mol. Pharmacol., 1996, 50, 1323-1329.
115. Nandanan, E.; Jang, S.Y.; Moro, S.; Kim, H. O.; Siddiqui, M. A.; Russ, P.; Marquez, V. E.; Busson, R.; Herdewijn, P.; Harden, T.K.; Boyer, J. L.; Jacobson, K. A. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y1 receptor ligands. J. Med. Chem., 2000, 43, 829-842.
116. Coller, B. S. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J. Clin. Invest., 1997, 99, 1467-1471.
117. Ammar, T.; Scudder, L. E.; Coller, B. S. In vitro effects of the platelet glycoprotein iib/iiia receptor antagonist c7e3 fab on the activated clotting time. Circulation, 1997, 95, 614-617.
118. Reverter, J. C. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J. Clin. Invest., 1996, 98, 863-874.
119. Furman, M. I. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb. Haemost., 2000, 84, 492-498.
120. Byzova, T. V.; Plow, E. F. Networking in the Hemostatic System. Intergrin aIIbb3 binds prothrombin and influences its activation J. Biol. Chem., 1997, 272, 27183-27188.
121. Udaya, S. T.; Amena, E.; Kevin, P. B.; Paul, A. G. Antiplatelet therapy: Current strategies and future trends. Future Cardiol., 2006, 2(3), 343-366.
122. Richard, C. B. New Thrombolytics, Anticoagulants, and Platelet Antagonists: The Future of Clinical Practice. J. Thromb Thrombolysis., 1999, 7, 195-220.
123. Agah, R.; Plow, E. F.; Topol, E. J. Platelets, 2nd edn. Elsevier/Academic Press, San Diego, 2007, 1145-1163.
124. PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and reperfusion Gain in Myocardial infarction (PARADIGM) trial. J. Am. Coll. Cardiol., 1998, 32, 2003-2010.
125. Muller, T. H.; Weisenberger, H.; Brickl, R.; Narjes, H.; Himmelsbach, F.; Krause, J.; Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation, 1997, 96, 1130-1138.
126. Kereiakes, D. J.; Kleiman, N. S.; Ambrose, J.; Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty J. Am. Coll. Cardiol., 1996, 27, 536-542.
127. Phillips, D. R.; Scarborough, R. M. Clinical pharmacology of eptifibatide. Am. J. Cardiol., 1997, 80(4A), 11B-20B.
128. Murphy, J.; Wright, R. S.; Gussak, I.; Williams, B.; Daly, R. N.; Cain, V. A.; Pieniaszek, H. J.; Sy, S.K.B.; Ebling, W.; Simonson, K.; Wilcox, R. A.; Kopecky, S. L. the use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am. J. Cardiovasc. Drugs, 2003, 3(2), 101-112.
129. Zablocki, J. A,; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M.; Zupec, M.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacquin, P.; Nicholson, N.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J.; Feigen, L. P. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (amino benzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J. Med. Chem., 1995, 38, 2378-2394.
130. Szalony, J. A.; Haas, N. F.; Salyers, A. K.; Taite, B. B.; Nicholson, N. S.; Mehrota, D. V.; Feigen, L. P. Extended Inhibition of Platelet Aggregation With the Orally Active Platelet Inhibitor SC-54684A. Circulation, 1995, 91, 411-416.
131. Reimann, J. D.; Modi, N. B.; Novotny, W. Pharmacokinetics and pharmaco dynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J. Clin. Pharmacol., 2000, 40(5), 488-495.
132. Merlos, M.; Graul, A.; Castaner, J. Sibrafiban. Drugs Fut., 1998, 23(12), 1297.
133. Christopher, P. C.; Carolyn, H.; Robert, G. W.; Anatoly, L.; Abraham, C.; Peter, B.; Jose, L. S.; Jiri, T.; Andrew, C.; Robert, J. A.; John, C. A.; Allan, S.; Eugene, B. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes. Circulation, 2000, 102(2), 149-156.
134. Fengqi, L.; Robert, M. C.; Steve, A. M.; Roger, C. C. Lotrafiban-SmithKline Beecham: An oral platelet glycoprotein IIb/IIIa blocker and related issues. Expert Opin. Investig. Drugs., 2000, 9(11), 2673-2687.
135. Mould, D.; Chapelsky, M.; Aluri, J.; Swagzdis, J.; Samuels, R.; Granett, J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin. Pharmacol. Ther., 2001, 69(4), 210-222.
136. Cohen, J. H.; Bos, M. E.; Cancian, S. C.; Harris, B. D.; Hortenstine, J. T.; Justus, M.; Maryanoff, C. A.; Mills, J.; Muller, S.; Roessler, A.; Scott, L.; Sorgi, K. L.; Villani, Jr. F. J.; Webster, R. R. H.; Weh. C. A practical synthesis of the platelet fibrinogen antagonist, Elarofiban. Org. Proc. Res. Dev., 2003, 7(6), 866-872.
137. Costanzo, M. J.; Hoekstra, W. J.; Maryanoff, B. E. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders WO, 97/41102, 1997.
138. Neil, E. S.; Hans-Christoph, D.; Gregory, W. A. Handbook of Clinical Neurology, 3rd series, Vol. 94, Amsterdam, Elsevier, 2009.
139. Bernat, A.; Savi, P.; Lale, A.; Hoffmann, P.; Herbert, J. M. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit. J. Cardiovasc. Pharmacol., 1999, 33(4), 573-579.
140. Savi, P.; Badorc, A.; Lalé, A.; Bordes, MF.; Bornia, J.; Labouret, C.; Berna, A.; de Cointet, P.; Hoffmann, P.; Maffrand, J. P.; Herbert, J. M. Rivaroxaban (BAY 59-7939)-An oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen Thromb Haemost., 1998, 80(3), 469-476.
141. Mark, K. O. S.; Justin, H.; Debra, A. H.; Walter, J.; Jean, M. H.; Jawed, F. The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys. Clin. Appl. Thromb Hemost., 2001, 7(1), 10-15.
142. Savi, P.; Zamboni, G.; Rescanières, O.; Herbert, J. M. Synergistic induction of tissue-type plasminogen activator (tPA) by vascular endothelial growth factor and basic fibroblast growth factor and localization of tPA to Weibel-Palade bodies in bovine micr ovascular endothelial cells. Thromb. Haemost., 2001, 85(4), 702-709.
143. Banno, H.; Kawazura, H.; Yutaka, T.; Sakuma, N.; Kitamori, T.; Hosoya, J.; Kibayashi, K.; Yamashita, H.; Umemura, K.; Nakashima, M. Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist. Eur. J. Pharmacol., 1999, 367(2-3), 275-282.
144. Ono, S.; Yoshida, T.; Maeda, K.; Kosaka, K.; Inoue, Y.; Imada, T.; Fukaya, C.; Nakamura, N. Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives. Chem. Pharm. Bull. (Tokyo), 1999, 47(12), 1694-1712.
145. Hans, U. S.; Wolfgang, G.; Bernd, J.; Melitta, J.; Otmar, K.; Wolfgang, K.; Volkmar, W.; Gerhard, Z. From a peptide lead to an orally active peptidomimetic fibrinogen receptor antagonist. Letters in Peptide Science, 1998, 5(2-3), 215-221.
146. Yoshio, H.; Jun, K.; Takeo, H.; Akira, T.; Kiyoko, I.; Yoshimi, T.; Michiko, M.; Hiroshi, M.; Tohru, A.; Takeo, O.; Yoshimi, S.; Emiko, Y.; Mako, Y.; Isao, U.; Iwao Ojima. GPIIb/IIIa Integrin Antagonists with the New Conformational Restriction Unit, Trisubstituted k-Amino Acid Derivatives, and a Substituted Benzamidine Structure. J. Med. Chem., 1998, 41(13), 2345-2360.
147. Egbertson, M. S.; Cook, J. J.; Bednar, B.; Prugh, J. D.; Bednar, R. A.; Gaul, S. L.; Gould, R. J.; Hartman, G. D.; Homnick, C. F.; Holahan, M. A.; Libby, L. A.; Lynch, J. J.; Lynch, R. J.; Sitko, G. R.; Stranieri, M. T.; Vasallo, L. M. Non-Peptide GPIIb/IIIa Inhibitors. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation. J. Med. Chem., 1999, 42(19), 4014.
148. Jennings, L. K.; Melanie, M.; White, B. A. Expression of ligandinduced binding sites on glycoprotein IIb/IIIa complexes and effect of various inhibitors. Amereican Heart Journal, 1998, Suppl.1, S179-S183.
149. Mehrotra, M. M.; Heath, J. A.; Rose, J. W.; Smyth, M. S.; Seroogy, J.; Volkots, D. L.; Ruhter, G. T.; Alaimo, L.; Park, G.; Pandey, A.; Robert, M. Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes. Bioorg. Med. Chem. Lett., 2002, 12(7), 1103-1107.
150. Peter, K.; Schwarz, M.; Bode, C. Activating Effects of GPIIb/IIIa Blockers: An Intrinsic Consequence of Ligand-Mimetic Properties. Circulation. 2002, 105, e180-e181.
151. Weiss, H. J.; Aledort, L. M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet., 1967, 2, 495-497.
152. Roth, G. J.; Majerus, P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest., 1975, 56, 624-632.
153. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
154. Lopez-Farre, A.; Caramelo, C.; Esteban, A.; Alberola, M. L.; Millas, I.; Monton, M.; Casado, S. Effects of Aspirin on Platelet-Neutrophil Interactions Circulation. 1995, 91, 2080-2088.
155. Vane, J. R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs. Nat. New Biol., 1971, 231, 232-235.
156. Roth, G. J.; Stanford, N.; Majerus, P. W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. USA, 1975, 72, 3073-3077.
157. Loll, P. J.; Picot, D.; Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol., 1995, 2, 637-643.
158. Patrono, C.; Coller, B.; Dalen, J. E. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest, 2001, 119(Suppl. 1), S39-S63.
159. Pedersen, A. K.; Fitz-Gerald, G. A. Cyclooxygenase inhibition, platelet function and metabolite formation during chronic sulfinpyrazone dosing. Clin. Pharmacol. Ther., 1985, 37, 36-42.
160. Rebuzzi, A. G.; Natale, A.; Bianchi, C. Effects of indobufen on platelet thromboxane B2 production in patients with myocardial infarction. Eur. J. Clin. Pharmacol., 1990, 39, 99-100.
161. Thomas, W. W.; Dale, W. Q. Ridogrel: An Antiplatelet Agent with Antihypertensive Properties. Cardiovasc. Drug Rev., 2000, 18(3), 222-231.
162. Bossche, H.V.; Willemsens, G.; Bellens, D.; Janssen, P.A.J. Ridogrel: A selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem. Pharmacol., 1992, 43(4), 739-744.
163. Wallace, J. L. In vivo antithrombotic effects of a nitric oxidereleasing aspirin derivative, NCX-4016. Thromb. Res., 1999, 93, 43-50.
164. Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.; Badimon, J, J. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J. Thromb. Haemost. 2004, 2, 492-498.
165. Dazoxiben. The Lancet. 1983, 321, 627-628.
166. Cowley, A. J.; Jones, E. W.; Carter, A. J.; Hanley, S. P.; Heptinstall, S. Effects of dazoxiben, an inhibitor of thromboxane synthetase, on forearm vasoconstriction in response to cold stimulation, and on human blood vessel prostacyclin production. Br. J. Clin. Pharmacol., 1985, 19, 1-8.
167. Lonsdale, R. J.; Heptinstall, S.; Westby, J. C.; Berridge, D. C.; Wenham, P. W.; Hopkinson, B. R.; Makin, G. S. Sulotroban. Thromb. Haemost., 1993, 69(2), 103-111.
168. Lumley, P.; White, B. P.; Humphrey, P. P. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br. J. Pharmacol., 1989, 97(3), 783-794.
169. Andrea, C.; Francesco, V. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc. Health Risk Manag., 2007, 3(1), 93-98.
170. Gian, G.; Neri, S.; Sergio, C.; Ettore, M.; Francesco, V. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study. Eur. Heart J., 2004, 25(20), 1845-1852.
171. Leger, A.J.; Jacques, S.L.; Badar, J.; Kaneider, N.C.; Derian, C.K.; Andrade-Gordon, P.; Covic, L.; Kuliopulos, A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation, 2006, 113(9), 1244-1254
172. Wu, C. C.; Teng, C. M. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur. J. Pharmacol., 2006, 546 (1-3), 142-147.
173. Wu, C, C.; Huang, S. W.; Hwang, T. L. YD-3, a novel inhibitor of protease-induced platelet activation. Br. J. Pharmacol., 2000, 130(6), 1289-1296.
174. Meadows, T. A.; Bhatt, D. L. Clinical Aspects of Platelet Inhibitors and Thrombus Formation. Circ. Res., 2007, 100(9), 1261-1275
175. Derian, C. K.; Damiano, B. P.; Addo, M. F. Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates. J. Pharmacol. Exp. Ther., 2003, 304(2), 855-861.
176. Damiano, B. P.; Derian, C. K.; Maryanoff, B. E. Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates. Cardiovasc.
177. De Mayer, S. F.; Vanhoorelbeke, K.; lrichts, H.; Staelens, S.; Feys, H. B.; Salles, I. Development of Monoclonal Antibodies that Inhibit Platelet Adhesion or Aggregation as Potential Anti-Thrombotic Drugs Cardiovasc. Hematol. Disord. Drug Targets, 2006, 6, 191-206.
178. Siljander, P. R.; Munnix, I. C.; Smethurst, P. A.; Deckmyn, H.; Linhout, T.; Quwehand, W. H. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood, 2004, 103, 1333-1341.
179. Hubbard, G. P.; Wolffram, S.; de Vos, R.; Bovy, A.; Gibbins, J. M. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J. Thromb. Haemost., 2004, 2, 2138-2145.
180. Huang, T. F.; Sheu, J. R.; Teng, C. M. A potent antiplatelet peptide, triflavin, from Trimeresurus flavoviridis snake venom. Biochem. J., 1991, 277, 351-357.
181. Teng, C. M.; Lin, C. H.; Lin, C. N.; Chung, M. I.; Haung, T. F. A hypotensive procyanidin-glycoside from Rhamnus formosana. Thromb Haemost., 1993, 70, 1014-1018.
182. Molina, V.; Carbajal, D.; Arruzazabala, L.; Mas R. A new compound with effects on arachidonic acid metabolites. J. Med. Food., 2005, 8, 232-236.
183. Haiso, G.; Lee, J. J.; Lin, K. H.; Shen, C. H.; Fong, T. H.; Chou, D. S. Characterization of a novel and potent collagen antagonist, caffeic acid phenethyl ester, in human platelets: In vitro and in vivo studies. Cardiovasc. Res., 2007, 75, 782-792.
184. Peng, M. L.; Lu, W. Q.; Beviglia, L.; Niewiarowski, S.; Kirby, E. P. Echicetin: A snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib. Blood, 1993, 81, 2321-2328.
185. Yeh, C. H.; Chang, M. C.; Peng, H. C.; Huang, T. F. Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. Br. J. Pharmacol., 2001, 132, 843-850.
186. Zhong, S. R.; Jin, Y.; Wu, J. B.; Chen, R. Q.; Jia, Y. H.; Wang, W. Y.; Xiong, Y. L.; Zhang, Y. Characterization and molecular cloning of dabocetin, a potent antiplatelet C-type lectin-like protein from Daboia russellii siamensis venom. Toxicon, 2006, 47, 104-112.
187. Chang, M. C.; Lin, H. K.; Peng, H. C.; Huang, T. F. Antithrombotic Effect of Crotalin, a Platelet Membrane Glycoprotein Ib Antagonist From Venom of Crotalus atrox. Blood, 1998, 91, 1582-1589.
188. Eisert, W. G. Platelets 2ndedn, Elsevier/Academic Press, San Diego, 2007, 1165-1179.
189. Ahrens, I.; Bode, C.; Peter, K. Inhibition of platelet activation and aggregation. Handb. Exp. Pharmacol., 2005, 170, 443-462.
190. Aktas, B.; Utz, A.; Hoenig-Liedl, P.; Walter, U.; Geiger, J. Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human Platelets: In Vitro and In Vivo/Ex Vivo Studies. Stroke, 2003, 34, 764-769.
191. Ikeda, Y.; Sudo, T.; Kimura, Y. Platelets 2nd edn, Elsevier/Academic Press, San Diego, 2007, 1181-1191.
192. Biondi-Zoccai, G. G. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention Am. Heart J., 2008, 155, 1081-1089.
193. Schror, K. The pharmacology of cilostazol. Diabetes Obes. Metab., 2002, 4(suppl 2), S14-S19.
194. Przyklenk, K.; Frelinger, A, L.; Linden, M. D.; Whittaker, P.; Li, Y.; Barnard, M. R.; Adams, J.; Morgan, M.; Al-Shamma, H.; Michelson, A. D. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J. Thromb. Haemost., 2010, 8(2), 331-340.
195. Gilbert, J. C.; DeFeo-Fraulini, T.; Hutabarat, R. M. First-in-Human Evaluation of Anti-von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers. Circulation, 2007, 116, 2678-2686.
196. http://www.clinicaltrials.gov/ct2/show/NCT00507338?term=tra+cer&rank= 1
197. Lasser, G.; Guchhait, P.; Ellsworth, J. L. C1qTNF-related protein-1 (CTRP-1): A vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood, 2006, 107, 423-430.